

**Formulary Motion History  
Bone Density Regulators (Osteoporosis)**

drugs reviewed	Motion	Date Reviewed	Motion & Second	Decision
alendronate risedronate ibandronate zoledronic acid calcitonin raloxifene teriparatide denosumab	<b>After reviewing the clinical information for the drugs within the bone density modulating class with the medically accepted indications, the prevention and treatment of osteoporosis, I move that no single brand or generic drug product in this class has a significant, clinically meaningful therapeutic advantage in terms of safety, efficacy, or clinical outcome for the treatment and prevention of osteoporosis for any sub-population. The branded products within the class do not have a significant meaningful clinical advantage over their generic equivalents and are excluded from the formulary. In light of their clinical equivalence, and after review of the average cost and drug utilization data of the medications in this class, all drugs except generic alendronate shall be removed from the formulary, in favor of less costly alternatives.</b>	October 17, 2012	Johnson Gaster	Passed Unanimous